Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07219472 · ClinicalTrials.gov registry record · NA

Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy

A NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy, sponsored by Case Comprehensive Cancer Center.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT07219472 is a NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 90 participants, below the 135-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07219472, a NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

This research study is for people who have a condition called chemotherapy-induced peripheral neuropathy (CIPN). This condition develops as a result of receiving medication(s) to treat cancer, particularly chemotherapy. CIPN is characterized by pain, numbness, tingling or burning sensations, typically in the hands and feet of people. These symptoms can lead to physical suffering, limited ability to perform daily activities, and low quality of life. One of the ways to treat CIPN is using a device called Scrambler Therapy. Scrambler Therapy was approved by the Food and Drug Administration (FDA) in 2009 as a treatment for CIPN. The treatment involves electrical signals passing through wires attached to parts of the body via adhesive tabs near where symptoms of CIPN are experienced. A standard treatment course consists of 10 daily sessions lasting about one hour each. The purpose of this study is to determine the effect of a 10-day course of Scrambler Therapy on symptoms of chemotherapy-induced peripheral neuropathy, day-to-day activities, overall quality of life, and use of pain medications. Participants will be randomly assigned to one of two groups. One group will receive Scrambler Therapy. The other group will not receive it. Participants will not know which group they were in until after treatment has completed. Participants in the group who did not receive Scrambler Therapy will have the opportunity to receive it after one month. Participants will be in this research study about 12 to 14 months.

Interventions

  • DEVICE Scrambler Therapy
  • OTHER Sham/No Intervention

Study Locations (1)

Ohio

  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute - Cleveland

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2026-04
Est. Completion 2027-12
Phase NA

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT07219472

The ClinicalTrials.gov registry entry for NCT07219472 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (33% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Scrambler Therapy is the first listed.

NCT07219472 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT07219472 about?

NCT07219472 is a clinical study titled "Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy". This research study is for people who have a condition called chemotherapy-induced peripheral neuropathy (CIPN). This condition develops as a result of receiving medication(s) to treat cancer, particularly chemotherapy. CIPN is characterized by pain, numbness, tingling or burning sensations, typical...

What is the current status of trial NCT07219472?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2026-04. Estimated completion is 2027-12.

What conditions does trial NCT07219472 study?

This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy.

What interventions are being tested in trial NCT07219472?

The interventions under investigation include: Scrambler Therapy (DEVICE), Sham/No Intervention (OTHER).

Who is sponsoring clinical trial NCT07219472?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07219472 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chemotherapy-induced Peripheral Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.